the color change mechanism. The compounds showed both blue and red shifts in photoluminescence and diffuse reflectance spectra upon grinding, indicating that mechanochromicluminescence in the hydrogen‐bonded complex is like its monomeric analogue and that aggregation structure plays an important role in mechanoresponsive behavior rather than the π‐conjugated structure. It was shown that a color change
molecular terminus are synthesized and their photoluminescence properties are investigated. The solidchromophore with a 4‐substituted pyridine ring exhibits a reversible photoluminescent color change, while the 2‐substituted chromophore shows only a small change in luminescence, and the 3‐substituted chromophore displays an irreversible photoluminescent color change with mechanical grinding. A change of
The instant invention provides for compounds which comprise benzoisoquinolinones and aza derivatives that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.
De Novo Designed Ru(II) Metallacycle as a Microenvironment‐Adaptive Sonosensitizer and Sonocatalyst for Multidrug‐Resistant Biofilms Eradication
作者:Yuling Xu、Yida Pang、Lishi Luo、Amit Sharma、Jingfang Yang、Chonglu Li、Shuang Liu、Jianbo Zhan、Yao Sun
DOI:10.1002/anie.202319966
日期:2024.4.8
Albeit sonodynamic therapy (SDT) has achieved encouraging progress in microbial sterilization, the scarcity of guidelines for designing highly effective sonosensitizers and the intricate biofilm microenvironment (BME), substantially hamper the therapeutic efficacy against biofilm infections. To address the bottlenecks, we innovatively design a Ru(II) metallacycle‐based sonosensitizer/sonocatalyst (named Ru‐A3‐TTD) to enhance the potency of sonotherapy by employing molecular engineering strategies tailored to BME. Our approach involves augmenting Ru‐A3‐TTD’s production of ultrasonic‐triggered reactive oxygen species (ROS), surpassing the performance of commercial sonosensitizers, through a straightforward but potent π‐expansion approach. Within the BME, Ru‐A3‐TTD synergistically amplifies sonotherapeutic efficacy via triple‐modulated approaches: (i) effective alleviation of hypoxia, leading to increased ROS generation, (ii) disruption of the antioxidant defense system, which shields ROS from glutathione consumption, and (iii) enhanced biofilm penetration, enabling ROS production in deep sites. Notably, Ru‐A3‐TTD sono‐catalytically oxidizes NADPH, a critical coenzyme involved in antioxidant defenses. Consequently, Ru‐A3‐TTD demonstrates superior biofilm eradication potency against multidrug‐resistant Escherichia coli compared to conventional clinical antibiotics, both in vitro and in vivo. To our knowledge, this study represents the pioneering instance of a supramolecular sonosensitizer/sonocatalyst. It provides valuable insights into the structure‐activity relationship of sonosensitizers and paves a promising pathway for the treatment of biofilm infections.